Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "allergy"

44 News Found

DCGI approves Themis Medicare's Viralex for Covid-19 treatment
News | March 03, 2022

DCGI approves Themis Medicare's Viralex for Covid-19 treatment

Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections


Amrita University launches wearable device for home monitoring of glucose and BP
Digitisation | March 02, 2022

Amrita University launches wearable device for home monitoring of glucose and BP

Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home


New data reinforces efficacy of Tezspire
Biotech | February 27, 2022

New data reinforces efficacy of Tezspire

These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting


Binnopharm acquires two anti-bacterial brands from Dr. Reddy’s
Biotech | February 21, 2022

Binnopharm acquires two anti-bacterial brands from Dr. Reddy’s

Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company


Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).


AptarGroup reported 2021 sales at US $3.23 billion
News | February 18, 2022

AptarGroup reported 2021 sales at US $3.23 billion

AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.


Morpen gets U.S. FDA approval for Fexofinadine
Drug Approval | December 05, 2021

Morpen gets U.S. FDA approval for Fexofinadine

Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever


Novartis showcases its attractive growth pipeline
News | December 03, 2021

Novartis showcases its attractive growth pipeline

Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint


Jubilant Pharmova consolidated PAT at Rs. 142.84 cr. in Q2FY22
News | October 22, 2021

Jubilant Pharmova consolidated PAT at Rs. 142.84 cr. in Q2FY22

The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment


SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment
Biotech | September 26, 2021

SAB Biotherapeutics’ SAB-185 moves to Phase 3 trial for Covid-19 treatment

Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors